In the weeks following a podcast appearance by actor Mel Gibson, pharmacies across the country recorded a 250 percent surge in ivermectin prescriptions among cancer patients — a drug developed for parasitic infections with no clinical evidence supporting its use against tumors. The moment illuminates something enduring and fragile about human hope: that when medicine feels uncertain, the voice of a familiar face in a vast digital room can carry more weight than years of clinical research. What is at stake is not merely the choice of one drug over another, but the time that cancer does not forg
Google News
· May 13, 2026
· health
· 1 min read
High
Sourcing: Verified
Ivermectin prescriptions surge 250% after Gibson's cancer claims on Rogan podcast
Cancer patients may delay or forgo proven treatments in favor of unproven alternatives, potentially compromising their health outcomes.
◉
Health & Medicine
8358 related articles
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% match
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% match
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% match
Related Coverage
The Guardian · Aug 24
UK approves daily GLP-1 pill for diabetes and weight loss amid counterfeit drug warnings
Foundayo, a new daily pill treating diabetes and aiding weight loss, launches in UK pharmacies Monday. Pharmacists welco…
Mirage News · Aug 24 Study reveals type 2 diabetes in lean Africans requires different treatment approachResearch reveals type 2 diabetes in lean Africans stems from insulin deficiency, not resistance, yet they receive the sa…
Mirage News · Aug 24 Australian researchers identify existing drugs to slow rare childhood dementiaAustralian researchers identified nine existing TGA-approved medicines that could slow brain damage in children with San…
The New Indian Express · Aug 24 Odisha leads national push to prevent metabolic liver disease affecting 1 in 3 IndiansLeading gastroenterology and hepatology experts convened in Odisha to finalize national guidelines for preventing metabo…
Bias & Framing
⚖
Article uses alarmist framing to highlight ivermectin prescription surge following celebrity endorsement, emphasizing lack of efficacy without exploring potential medical rationales or patient autonomy.
Bias Direction
center-left
Confidence
HIGH
Crisis/danger framing combined with celebrity-blame narrative. The surge is presented as problematic consequence of misinformation rather than exploring legitimate medical inquiry or patient agency. Repeated use of 'controversial,' 'unproven,' and 'alternative' creates negative valence.
controversial drug
surged 250%
unproven antiparasitic treatments
lack of proven efficacy
touted it
might be the reason why
Oncologists or researchers exploring ivermectin's potential mechanisms in cancer treatment
Patient testimonials or rationales for seeking the treatment
Regulatory or medical establishment perspective on off-label drug use
Data on whether prescriptions came from licensed physicians or alternative practitioners
Context on other celebrity health endorsements and their actual impact on prescribing patterns
Discussion of informed consent and patient autonomy in treatment decisions
Geopolitical Impact
🌎
This is a public health/medical misinformation issue, not a geopolitical matter. No international implications or power dynamics between nations are present.
Escalation Risk
low
Confidence
HIGH
Not applicable - this concerns domestic public health policy and medical misinformation, not international relations or geopolitical competition.
Economic Lens
📈
Ivermectin prescriptions for cancer surged 250% following celebrity endorsement on podcast, raising concerns about unproven treatments and healthcare market distortion.
Market Signal
bearish
Confidence
HIGH
Pharmaceutical/Drug Manufacturing
Healthcare Services
Medical Devices & Diagnostics
Insurance Industry
Media & Entertainment
Consumers may waste healthcare resources and out-of-pocket spending on unproven treatments, potentially delaying effective cancer therapies. Insurance costs may rise due to off-label prescriptions. Vulnerable cancer patients face financial and health risks from misinformation-driven treatment decisions.
Potential FDA scrutiny of off-label ivermectin promotion; possible regulatory action against misleading health claims on media platforms; consideration of stricter social media health claim guidelines; potential insurance coverage restrictions for unproven cancer treatments; possible Congressional inquiry into influencer-driven pharmaceutical demand.